Ars Pharmaceuticals Inc (SPRY) Stock Price, Quote & News

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 771 9307

Website: ars-pharma.com

Address:

11682 El Camino Real, Suite 300, San Diego, United States

Stone52 May. 18 at 6:54 PM

$AQST large volume sales or shorts today. $SPRY CVS Caremark deal coming in the next 30 days. AQST doesn’t yet have FDA approval of study design. SPRYs Neffy has been approved around the world. Too little, too late for AQST.

1 · Reply

Stockpsad May. 18 at 3:55 PM

$SPRY so interesting how Third Point took a position in ARS...

1 · Reply

SonOfPaul19 May. 18 at 9:30 AM

$SPRY great 13f adds…

0 · Reply

MassNortheast May. 16 at 12:22 AM

$SPRY $NDAQ $34 PT?

1 · Reply

ae1213 May. 16 at 12:10 AM

$AQST $SPRY @BigGainTom Peter the First used to say “Let everyone speak for themself, so their stupidity be obvious to everybody”. Your logic is really something! Thank you for sharing.

0 · Reply

BigGainTom May. 15 at 10:18 PM

Critical to notice the following: $AQST Moved up big yesterday and moved down today to close the gap before it can move up again. $SPRY Was down yesterday, down again today, moved up to close the opening gap, and went down again. One has a future (AQST) and one doesn't (SPRY)

2 · Reply

Stone52 May. 15 at 9:06 PM

$SPRY Rubric Capital increased from 6.2 million shares to 8 million shares.

1 · Reply

Stone52 May. 15 at 8:56 PM

$SPRY thank you Dan Loeb and Third Point

0 · Reply

SonOfPaul19 May. 15 at 8:12 PM

$SPRY love it. The option market makers successfully cleaned out the May 7.5 calls. There was HUGE open interest on them almost 7k calls to 700 puts. Option market makers who sold the calls successfully got the price down from 9.57 last week to 7.425 at expiry effectively making these OTM. They also used the massive algo selling from this mornings widened loss to flash crash the share price. A powder keg is brewing. The massive short interest will need to start covering with the CVS announcement forthcoming. We have all the ingredients. CVS and Donn Casale leading the way. This is a winner.

0 · Reply

Ohzipit May. 15 at 6:40 PM

$SPRY RJ update. Remains Strong Buy price target $34

1 · Reply

ARS Pharmaceuticals Earnings Call Transcript: Q1 2026

2026-05-15T11:05:17.000Z - 3 days ago

Options Volatility and Implied Earnings Moves Today, May 15, 2026

DSX RBC SACH SKLZ SURG

2026-05-15T10:07:53.000Z - 3 days ago

ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)

May 15, 2026, 6:00 AM EDT - 3 days ago

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

May 13, 2026, 8:00 AM EDT - 5 days ago

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

May 7, 2026, 8:00 AM EDT - 11 days ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

2026-04-15T10:11:10.000Z - 4 weeks ago

ARS Pharmaceuticals announces Health Canada approval of neffy 2 mg

Apr 15, 2026, 6:05 AM EDT - 4 weeks ago

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

2026-04-09T11:14:32.000Z - 5 weeks ago

ARS Pharmaceuticals initiated with an Outperform at Northland

2026-04-09T11:13:02.000Z - 5 weeks ago

Northland starts disruptor ARS Pharmaceuticals with an Outperform

2026-03-27T12:16:24.000Z - 7 weeks ago

ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement

Mar 27, 2026, 8:00 AM EDT - 7 weeks ago

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

Mar 11, 2026, 8:00 AM EDT - 2 months ago

ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:30 AM EDT - 2 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-03-09T10:05:06.000Z - 2 months ago

ARS Pharmaceuticals reports Q4 EPS (42c), consensus (44c)

Mar 9, 2026, 6:00 AM EDT - 2 months ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

Feb 23, 2026, 8:00 AM EST - 3 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Feb 10, 2026, 8:00 AM EST - 3 months ago

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

2026-02-02T13:11:39.000Z - 3 months ago

ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy

Feb 2, 2026, 8:00 AM EST - 3 months ago

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to

2026-01-21T13:10:51.000Z - 4 months ago

ARS Pharmaceuticals announces California eligible for neffyinSchools program

Jan 21, 2026, 8:00 AM EST - 4 months ago

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

2026-01-09T14:40:36.000Z - 4 months ago

ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James

AQST

2025-12-29T13:10:25.000Z - 5 months ago

ARS Pharmaceuticals announces NMPA approval for neffy 2 mg

Dec 29, 2025, 8:00 AM EST - 5 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

Dec 3, 2025, 2:30 PM EST - 5 months ago

ARS Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 8:00 AM EST - 6 months ago

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

2025-11-11T20:30:19.000Z - 6 months ago

ARS Pharmaceuticals management to meet with Oppenheimer

2025-11-11T13:50:42.000Z - 6 months ago

ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer

Nov 10, 2025, 8:30 AM EST - 6 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2025

2025-11-10T11:11:20.000Z - 6 months ago

ARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)

Nov 10, 2025, 6:00 AM EST - 6 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

2025-11-04T13:25:11.000Z - 6 months ago

ARS Pharmaceuticals launches ‘Get neffy on Us’

Nov 4, 2025, 8:00 AM EST - 6 months ago

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Nov 3, 2025, 2:23 PM EST - 7 months ago

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Nov 3, 2025, 8:00 AM EST - 7 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

Nov 3, 2025, 7:45 AM EST - 7 months ago

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 8, 2025, 8:00 AM EDT - 7 months ago

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

Sep 29, 2025, 4:05 PM EDT - 8 months ago

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Sep 17, 2025, 9:00 AM EDT - 8 months ago

ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

Sep 8, 2025, 8:00 AM EDT - 9 months ago

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Sep 3, 2025, 3:55 PM EDT - 9 months ago

ARS Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 9 months ago

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 13, 2025, 8:30 AM EDT - 9 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 9 months ago

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

Aug 4, 2025, 8:00 AM EDT - 10 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

Jul 18, 2025, 9:25 AM EDT - 10 months ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Jun 4, 2025, 5:30 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:20 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: 45th Annual William Blair Growth Stock Conference

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

May 7, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 5, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 4:10 PM EST - 1 year ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Mar 3, 2025, 4:35 PM EST - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Feb 20, 2025, 7:02 PM EST - 1 year ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Feb 18, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 12, 2025, 2:40 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Jan 15, 2025, 10:30 AM EST - 1 year ago

ARS Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Dec 19, 2024, 5:25 PM EST - 1 year ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Dec 12, 2024, 2:32 PM EST - 1 year ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Dec 4, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Nov 18, 2024, 2:25 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 1:00 PM EST - 1 year ago

ARS Pharmaceuticals Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 6:30 AM EST - 1 year ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 11, 2024, 7:00 AM EST - 1 year ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Nov 9, 2024, 5:30 PM EST - 1 year ago

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Oct 24, 2024, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Stone52 May. 18 at 6:54 PM

1 · Reply

Stockpsad May. 18 at 3:55 PM

$SPRY so interesting how Third Point took a position in ARS...

1 · Reply

SonOfPaul19 May. 18 at 9:30 AM

$SPRY great 13f adds…

0 · Reply

MassNortheast May. 16 at 12:22 AM

$SPRY $NDAQ $34 PT?

1 · Reply

ae1213 May. 16 at 12:10 AM

$AQST $SPRY @BigGainTom Peter the First used to say “Let everyone speak for themself, so their stupidity be obvious to everybody”. Your logic is really something! Thank you for sharing.

0 · Reply

BigGainTom May. 15 at 10:18 PM

2 · Reply

Stone52 May. 15 at 9:06 PM

$SPRY Rubric Capital increased from 6.2 million shares to 8 million shares.

1 · Reply

Stone52 May. 15 at 8:56 PM

$SPRY thank you Dan Loeb and Third Point

0 · Reply

SonOfPaul19 May. 15 at 8:12 PM

0 · Reply

Ohzipit May. 15 at 6:40 PM

$SPRY RJ update. Remains Strong Buy price target $34

1 · Reply

omega42 May. 15 at 6:32 PM

$SPRY so according to MD&A, they spend 72M which included additional 26M of selling and marketing expense to get 23M of revenue. That's a fantastic business model and keep up a good work

1 · Reply

SonOfPaul19 May. 15 at 6:13 PM

$SPRY $AQST

2 · Reply

SonOfPaul19 May. 15 at 4:46 PM

$SPRY $AQST I think @BigGainTom is finally starting realize he’s on the wrong horse!

1 · Reply

ae1213 May. 15 at 4:43 PM

$SPRY $AQST you are really desperate! Try to chillaxe, it is almost weekend

0 · Reply

ae1213 May. 15 at 4:41 PM

$AQST $SPRY Hey silly sally, it is not for nothing that they say “a little bit of knowledge is dangerous”. Now that the business picture is much more clear, the short interest here is an explosive fuel which will propel $SPRY in the coming weeks and months

0 · Reply

MarketBeat May. 15 at 4:10 PM

https://marketbeat.com/a/8656861/ $SPRY ARS Pharmaceuticals Q1 Earnings Call Highlights

1 · Reply

EarningsInsider May. 15 at 3:30 PM

https://www.marketbeat.com/earnings/reports/2026-5-15-ars-pharmaceuticals-inc-stock/ $SPRY ARS Pharmaceuticals Earnings Transcript

1 · Reply

StockBraker May. 15 at 2:56 PM

$SPRY

3 · Reply

SonOfPaul19 May. 15 at 2:54 PM

$SPRY and to all the $AQST fanboys who keep mentioning the cash burn and liabilities…go read the transcript to the call. The Cantor bear analyst who has a low $12 price target (same firm who just ran the oak tree loan for rival AQST) asked about the math on the breakeven…CEO had a fantastic response and shut down any need for dilution…remember the $150MIL untapped credit facility ARS has (probably won’t be needed anyway).

1 · Reply

SonOfPaul19 May. 15 at 2:50 PM

$SPRY this will explode over next few months. All signs leading to CVS Caremark unlocking. Casale is huge hire to ramp up those retail sales. Today low price is algos crushing the widened loss and options pinning on the $8 dollar calls. Huge bear trap this morning on the flash crash to 6.27. Someone loaded up 300k shares on that downswing. This is as cheap as you will get. Can’t wait for the next few months!

0 · Reply

StockBraker May. 15 at 1:58 PM

$SPRY

1 · Reply

ae1213 May. 15 at 1:47 PM

$AQST $IOVA $SPRY hey silly sally, go back to your “high power job”. While driving my garbage truck, I have learnt how to smell a rat $AQST Looks like you have read the writing on the wall

0 · Reply

Market Cap	737.31M
Revenue (ttm)	84.28M
Net Income (ttm)	-171.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-203.25%
Debt to Equity Ratio	1.47

Volume	2,142,800
Avg Vol	1,724,280
Day's Range	N/A - N/A
Shares Out	99.30M
Stochastic %K	11%
Beta	0.93
Analysts	Strong Sell
Price Target	$24.25